FibroGen, Inc. (NASDAQ:FGEN) registered a -6.44% decrease, still its new closing price is 51.60% up from the company’s 1 year high of 25.70.It posted -9.54% losses in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 7 stock analysts following this company have an average price target at $40.17, with individual PT in the $31.00-$52.00 range. The shares moved at $21.80, implying that brokerage firms see shares gaining about 7.50% in twelve months time.

FibroGen, Inc. (FGEN) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 1.87% rise year to date. A CEO, 10% Owner at FibroGen, Inc. (FGEN) offloaded shares in a transaction closed on Friday January 27, 2017. Neff Thomas B sold 37,798 shares in the company at $23.29 each and collected $880,000 in proceeds. Neff Thomas B now owns 3,490,793 shares in the company after this transaction. A Director in the company, Kurkijarvi Kalevi, disclosed a transaction on Thursday January 19, 2017 that ended up generating $49,001 from the sale of 2,000 shares at $24.9 per share.

FibroGen, Inc. (NASDAQ:FGEN) Upcoming Results on Tap

FibroGen, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.35 in that period. Sales during the quarter are predicted to arrive at $28.3 million.

Earnings surprise history: Last quarter, the company posted approximately $30.1 million in revenue and EPS of $-0.38. The mean forecast was for $24.25 million and $-0.60 a share, respectively. One quarter earlier, revenue for the stock was at $89.28 million, with earnings at $0.35/share.

FibroGen, Inc. (FGEN) Brokerage Update

FibroGen, Inc. (FGEN) is in Credit Suisse’s research list so their analyst rating change is noteworthy. These shares were upgraded to Outperform from Neutral by Credit Suisse, according to news reported on Thursday February 11, 2016.Another important research note was issued by Goldman on Monday July 20, 2015.The firm upgraded FGEN to Buy from Neutral. Over the last six months and over the last three months, the shares of FibroGen, Inc. (FGEN), have changed 13.96% and 32.93%, respectively.